Aridis Pharmaceuticals, Inc.
5941 Optical Court
34 articles with Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infections, today reported financial and corporate results for the first quarter ended March 31, 2019.
Aridis Pharmaceuticals Announces 2018 Fourth Quarter and Year-End Financial Results and Business Update
The Company, which is utilizing its proprietary MabIgX® antibody discovery platform to develop novel therapies for hospital acquired infections made considerable clinical development advances with its lead monoclonal antibody programs, AR-301 and AR-105, along with its cystic fibrosis (CF) candidate AR-501, an inhalable therapy to treat chronic lung infections impacting CF patients.
AR-501 (Cystic Fibrosis) Enrolls First Subject in Phase 1/2a Clinical Trial for Treatment of Chronic Lung Infections in Cystic Fibrosis Patients
Two-Part Randomized, Double-Blinded Placebo Controlled Clinical Study in Healthy Subjects Followed by Cystic Fibrosis Patients Enrolls First Adult Human Volunteer
Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program Designations
CF Foundation expands research agreement for AR-501 (for cystic fibrosis) to include additional award amount of up to $4.6 million
Completed an initial public offering on August 16 and began trading on the Nasdaq Capital Market
Aridis Pharmaceuticals Announces Publication of Positive AR-301 Phase 1/2a Data in "Intensive Care Medicine" and "The Lancet Respiratory Medicine"
Positive safety and efficacy trends of AR-301 in Phase 1/2a clinical trial was presented at the 31st Annual Congress of the European Society of Intensive Care Medicine
Aridis Pharmaceuticals, headquartered in San Jose, California, announced it had added broad patent coverage of two of its product candidate monoclonal antibodies.
Aridis Pharmaceuticals Strengthens Intellectual Property Portfolio With Additional Broad Patent Coverage For Multiple Product Candidates
New patents add to previously issued U.S. and international counterpart patents and patent applications that form Aridis's fully human monoclonal antibody patent portfolio
Aridis Pharmaceuticals, Inc. announced the pricing of its initial public offering of 2,000,000 shares of its common stock at a public offering price of $13.00 per share for total gross proceeds of $26.0 million
Aridis Pharmaceuticals, Inc. today announced that it has launched an initial public offering of 2,000,000 shares of its common stock.
Aridis Pharmaceuticals Forms Subsidiary to Develop and Market its Monoclonal Antibody Therapies in China
Aridis Pharmaceuticals, Inc. today announced that it has created a joint venture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (Hepalink), one of China's leading pharmaceutical companies.
Aridis Pharma Enrolls First Patients In Global Pivotal Clinical Trial Of Novel Monoclonal Antibody For Treating Acute Pneumonia
Aridis Pharma Presents Positive Phase IIa Safety And Efficacy Data Of Salvecin (AR-301) In Patients With Severe Pneumonia Caused By Staphylococcus Aureus During The 2017 ASM Microbe Congress
Aridis Pharma Reports Positive Clinical Data From Phase 1/2a Study Of Human Monoclonal Antibody AR-301 For Treating Pneumonia
Aridis Pharmaceuticals Expands The Company's Clinical Advisory Board; Adds Three Industry Veterans With Unique Expertise In The Field
Aridis Pharmaceuticals Strengthens Board Of Directors With Former Wyeth (Now Pfizer President Of R&D Robert Ruffolo, Jr.
Aridis Pharmaceuticals Expands Patent Portfolio For Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets